Press Releases Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 Sep 03, 2026 Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data Aug 27, 2026 Vaxcyte to Participate in Upcoming Investor Conferences Aug 05, 2026 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Jul 08, 2026 Vaxcyte to Participate in Upcoming Investor Conferences Jun 02, 2026 Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults May 06, 2026 Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update Apr 07, 2026 Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference Mar 23, 2026 Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Mar 18, 2026 Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Feb 24, 2026 Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 17
Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 Sep 03, 2026 Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data Aug 27, 2026 Vaxcyte to Participate in Upcoming Investor Conferences Aug 05, 2026 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Jul 08, 2026 Vaxcyte to Participate in Upcoming Investor Conferences Jun 02, 2026 Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults May 06, 2026 Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update Apr 07, 2026 Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference Mar 23, 2026 Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Mar 18, 2026 Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Feb 24, 2026 Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 17
